About CreatiPhage

Director of the Fudan University Phage Institute, Founding Director of the Shanghai Institute of Phage, and Chairman of the Alliance Phage of China. He previously served as Vice President of Zhongshan Hospital, Fudan University, Director of the Shanghai Public Health Clinical Center, and Deputy Director of the Shanghai Shenkang Hospital Development Center.

He initiated China’s first clinical trial of phage therapy, has led two major national phage therapy programs, and has achieved several landmark firsts in the field of phage therapy.

Founding Deputy Director of the Shanghai Institute of Phage and AMR; Head of the Department of Laboratory Medicine and of Clinical Pathology at Hualien Tzu Chi Medical Center; Director of Experimental Diagnostics at the Tzu Chi University School of Medicine; Chair of the hospital’s Biosafety Committee; member of Taiwan’s eastern-region infection and epidemic management committee; and reviewer of level-3 biosafety containment facilities for the disease control authority. He is a certified specialist in clinical pathology, genomic medicine and emergency medicine.

He previously served as Dean of the Tzu Chi University School of Medicine, and held research appointments at the Institute of Molecular Biology of Academia Sinica in Taipei, the Icahn School of Medicine at Mount Sinai in New York, and the University of Pennsylvania.

Before retirement she was Director and academic leader of the Department of Urology and Director of the Superbug Treatment Department at the Shanghai Public Health Clinical Center.

Her research focuses on urological cancers, urinary tuberculosis, refractory urinary tract infections and the clinical application of phage therapy. As clinical lead she participated in more than 30 phage therapy cases for urinary tract infections. She has published papers in journals including Emerging Microbes & Infections and Frontiers in Cellular and Infection Microbiology, and was first author of the first reported phage therapy case paper in China.

Grade-II professor, Changjiang Scholar of the Ministry of Education, and recipient of the State Council Special Allowance. He is Director of the Department of Infectious Diseases and of the Infection Management Department at Zhongshan Hospital, Fudan University; Deputy Director of the Shanghai Institute of Respiratory Diseases and Head of its Pulmonary Infection Research Laboratory; Director of the Shanghai Hospital Infection Quality Control Center; and Deputy Director of the Fudan University Phage Research Institute.

He served on the national and Shanghai COVID-19 medical treatment expert panels and chaired Shanghai’s expert panel on COVID-19 hospital infection prevention and control. He is a member of the academic committee of the Shanghai Institute of Phage and AMR; Vice Chair of the Chinese Medical Association’s branch of bacterial infection and antimicrobial resistance control; Vice Chair of the National Health Commission’s expert committee on healthcare-associated infection prevention; Director of the National Health Commission’s hospital administration institute training base for bacterial and fungal infection diagnosis and treatment; a World Health Organization (WHO) expert on multidrug-resistant organisms and healthcare-associated infection prevention; and founder of the Shanghai International Forum for Infection Control (SIFIC). Under his leadership, the Zhongshan infection diagnosis, treatment and prevention center received the 2020 Shanghai Municipal Government Quality Gold Award.

His main research direction is the precise diagnosis, treatment and prevention of infectious diseases. He has led more than ten projects funded by the National Natural Science Foundation of China, subtasks of the Ministry of Science and Technology’s major research programs, the Shanghai Science and Technology Commission, and the Shanghai Shenkang Hospital Development Center.

The source lists Xiaokui Guo as Distinguished Professor at Shanghai Jiao Tong University; Deputy Director of the National Center for Tropical Diseases Research; Executive Vice Dean of the university’s School of Global Health; Vice Dean of the Shanghai–Ottawa Joint School of Medicine; and Deputy Director of the Shanghai Institute of Phage and AMR.

His professional appointments include chair of the Chinese Preventive Medicine Association’s microecology branch; chair of the Chinese Society for Microbiology’s medical microbiology and immunology committee and its science communication and education committee; and vice president and secretary-general of the Shanghai Society for Microbiology. He is a nationally recognized distinguished university teacher and outstanding teacher. He leads the national model and shared course Medical Microbiology and edited Pathogen Biology textbooks in the national undergraduate and graduate textbook programs for the 11th and 12th Five-Year Plans.

Jinhong Qin is a professor at Shanghai Jiao Tong University School of Basic Medical Sciences. The source lists her as vice chair of the youth committee of the Chinese Preventive Medicine Association’s microecology branch; secretary and member of the bacteriology group of the Chinese Society for Microbiology’s medical microbiology and immunology committee; and a member of committees on infectious microecology, special pathogens and Shanghai preventive microecology.

Her research focuses on phages and the prevention and control of resistant bacteria. The source reports more than 20 SCI-indexed papers and leadership or participation in projects funded by the National Natural Science Foundation, major national programs, Shanghai’s science authority and the Ministry of Education. She edited The Human Microbiome and Health and contributed to textbooks on pathogenic microbiology and the human microbiome.

Jingmin Gu is a leading professor and doctoral supervisor at Jilin University. His research addresses the need to overcome antimicrobial-resistant bacteria through therapeutic phages and antibacterial proteins targeting important resistant zoonotic pathogens, as well as the mechanisms of phage–host interactions.

He has led national research projects including an Excellent Young Scientists Fund award, general grants from the National Natural Science Foundation, and a National Key R&D Program subproject. The source cites publications in journals including PLOS Pathogens and Biosensors and Bioelectronics.

Co-founder and CEO of CreatiPhage Biotechnology, Associate Researcher at the Fudan University Phage Institute, and industry mentor for master’s students at the College of Food Science and Technology, Huazhong Agricultural University. Before joining CreatiPhage, he was an Associate Research Fellow and master’s supervisor at the Shanghai Institute of Phage, Shanghai Public Health Clinical Center.

His work focuses on the research and application of medical phage therapy. He has led a subtask of the Ministry of Science and Technology’s frontier biotechnology major program, general and young-scientist projects of the National Natural Science Foundation of China, a general project of the Shanghai Natural Science Foundation, and Pioneer Program projects, and has led or contributed to numerous phage therapy papers, consensus statements, standards and guidelines, as well as monographs and textbooks including Phagology and Microbial Virology.

He currently serves as a member of the Phage Technology Committee of the Chinese Society of Biotechnology, head of the Alliance Phage of China’s vice-chair unit, editorial board member of Bacteriophage and Microbes & Immunity, scientific editor of Military Medical Research, and expert of the virtual teaching and research office for microbial virology, a key area of virology.

Mengjun Cheng received her PhD from Jilin University. The source lists her as an assistant research fellow at Shanghai Public Health Clinical Center and the Shanghai Institute of Phage and AMR.

Her work concerns clinical phage therapy, phage antibacterial proteins and molecular mechanisms of bacterial resistance to phages. She has led one Young Scientists Fund project of the National Natural Science Foundation of China and one youth clinical-research project funded by the Shanghai health authority. The source reports seven first- or co-first-author SCI-indexed papers in journals including Applied and Environmental Microbiology, Viruses and Frontiers in Microbiology.